drugset / Trial / NCT07223034
A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1
Recruiting
20 enrolled
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Timeline
- Start
- 2025-10-27
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | — | — |
| Background | Temozolomide | Small molecule | — | Oral |